Radiation and immunotherapy before chemo for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new approach for breast cancer that combines a short course of focused radiation (SBRT) with an injection of the immunotherapy drug pembrolizumab directly into the tumor, followed by standard chemotherapy before surgery. The goal is to see if this combination helps shrink the tumor more effectively before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called invasive ductal carcinoma (the most common type), but not certain rare subtypes like sarcomatous or metaplastic.
- Your cancer is stage IIB or III, and if you have triple-negative or HER2-positive breast cancer, stage IIA may also be eligible.
- Your doctor can feel the tumor during a physical exam.
- You are scheduled to receive chemotherapy before surgery (neoadjuvant chemotherapy).
- You are 18 or older and able to safely have a needle biopsy and an injection of the immunotherapy drug pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat triple-negative breast cancer before surgery by combining radiation therapy with an immunotherapy drug and chemotherapy. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This trial tests giving immunotherapy combined with a precise, high-dose radiation boost before surgery for HER2-negative breast cancer. The goal is to see if this approach can improve outcomes, especially for cancers that are more advanced or have spread to a few other spots in the body.
This trial tests a new combination of radiation plus an immunotherapy drug (pembrolizumab) to help your immune system fight metastatic triple-negative breast cancer after a prior immunotherapy has stopped working. The goal is to see if adding radiation can boost your body's response to treatment.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy before surgery improves immune and clinical responses in people with early-stage triple-negative breast cancer. You may benefit by getting a potentially more effective treatment plan, while the study team closely monitors your response.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.